Roen Health, Inc. dba RoenRx – FDA Warning Letter, Mar 1, 2026

In June 2026, the U.S. Food and Drug Administration (FDA) issued a warning letter to Roen Health, Inc., doing business as RoenRx, following a website review conducted in March 2026. The FDA identified significant violations related to the marketing of compounded semaglutide products. The primary issues involve false or misleading claims that result in the products being considered misbranded under the Federal Food, Drug, and Cosmetic Act. Specifically, the FDA noted that RoenRx’s website erroneously suggested the company was the manufacturer of the drugs and implied that these compounded products were FDA-approved by comparing them to brand-name medications like Ozempic and Wegovy. In reality, compounded drugs do not undergo the same federal safety and effectiveness reviews as approved medications. Under the regulatory framework of the FD&C Act, such representations are prohibited. The FDA has mandated that RoenRx investigate the root causes of these violations and implement corrective actions to ensure future compliance. The company is required to respond in writing within 15 business days, detailing the steps taken to address the issues, identifying the actual manufacturers of the products, and providing evidence that misleading website claims have been corrected or removed. Failure to resolve these violations may result in legal action, including product seizures or injunctions.